TORONTO, June 27 /CNW/ - Amorfix Life Sciences (TSX-V:AMF), a company focused on diagnostics and treatments for brain wasting diseases, today announced that Dr. Neil Cashman, Chief Scientific Officer of Amorfix, presented an overview of the Company’s proprietary Epitope Protection (EP) technology for the in vitro detection of variant Creutzfeldt-Jacob Disease (vCJD) at the Transmissible Spongiform Encephalopathies (TSE) Conference held earlier today in Berlin, Germany. The presentation entitled, “Detection of vCJD prions in blood using epitope protection” highlighted the sensitivity and specificity of the EP-vCJD(TM) high-throughput diagnostic test for screening blood donations.
